Search by Drug Name or NDC

NDC 00002-7716-01 Portrazza 16 mg/mL Details

Portrazza 16 mg/mL

Portrazza is a INTRAVENOUS SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Eli Lilly and Company. The primary component is NECITUMUMAB.

MedlinePlus Drug Summary

Necitumumab injection is used with gemcitabine (Gemzar) and cisplatin to treat a certain type of non-small-cell lung cancer (NSCLC) that has spread to other parts of the body. Necitumumab injection is in a class of medications called monoclonal antibodies. It works by helping your immune system to slow or stop the growth of cancer cells.

Related Packages: 00002-7716-01
Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Necitumumab Injection

Product Information

NDC	00002-7716
Product ID	0002-7716_de61c9cb-64bb-475a-9b6a-dde617a87e4a
Associated GPIs	21360054002020
GCN Sequence Number	075209
GCN Sequence Number Description	necitumumab VIAL 800MG/50ML INTRAVEN
HIC3	V1W
HIC3 Description	ANTINEOPLASTIC EGF RECEPTOR BLOCKER MCLON ANTIBODY
GCN	40219
HICL Sequence Number	042835
HICL Sequence Number Description	NECITUMUMAB
Brand/Generic	Brand
Proprietary Name	Portrazza
Proprietary Name Suffix	n/a
Non-Proprietary Name	necitumumab
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	SOLUTION
Route	INTRAVENOUS
Active Ingredient Strength	16
Active Ingredient Units	mg/mL
Substance Name	NECITUMUMAB
Labeler Name	Eli Lilly and Company
Pharmaceutical Class	Epidermal Growth Factor Receptor Antagonist [EPC], HER1 Antagonists [MoA]
DEA Schedule	n/a
Marketing Category	BLA
Application Number	BLA125547
Listing Certified Through	2024-12-31

Package

NDC 00002-7716-01 (00002771601)

Pricing Information	N/A
NDC Package Code	0002-7716-01
Billing NDC	00002771601
Package	1 VIAL, SINGLE-USE in 1 CARTON (0002-7716-01) / 50 mL in 1 VIAL, SINGLE-USE
Marketing Start Date	2015-11-24
NDC Exclude Flag	N